

NOTIFICATION OF PARTICIPATION AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

To be received by Vicore Pharma Holding AB (publ) no later than 4 March 2021.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, at the extraordinary general meeting on 5 March 2021. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions:

- Complete the information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Vicore Pharma Holding AB (publ), att: Nina Carlén, Kronhusgatan 11, SE-411 05 Göteborg. A completed and signed form may also be submitted electronically and shall, in such case, be sent to nina.carlen@vicorepharma.com

- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- A power of attorney shall be enclosed if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form
- **Please note that a shareholder whose shares are registered in the name of a bank or securities institute must register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be received by the company no later than 4 March 2021. An advance vote can be withdrawn up to and including 4 March 2021 by contacting nina.carlen@vicorepharma.com.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and complete proposals on the company's website. The complete proposals are provided on the company's website no later than three weeks before the general meeting.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Extraordinary general meeting in Vicore Pharma Holding (publ) on 5 March 2021

The voting options below comprise, if not otherwise stated in the form, the proposals included in the notice convening the general meeting.

The voting list proposed to be approved under item 3 below is the voting list prepared by the company, based on the shareholders' register for the general meeting and the advance votes received, as verified by the persons elected to approve the minutes.

The tasks of the persons elected to approve the minutes also include verifying the voting list and that the advance votes received are correctly reflected in the minutes.

1. Election of a chairman at the extraordinary general meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
2. Election of one or two persons who shall approve the minutes of the meeting
2.1 Kjell Stenberg or, in the event of impediment, the person instead appointed by the board of directors Yes <input type="checkbox"/> No <input type="checkbox"/>
2.2 Johannes Eckerstein or, in the event of impediment, the person instead appointed by board of directors Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Preparation and approval of the voting list Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Determination of whether the meeting was duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Resolution on the board of directors of Vicore Pharma Holding AB (publ)'s resolution on a directed issue of new shares Yes <input type="checkbox"/> No <input type="checkbox"/>

The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting
(Completed only if the shareholder has such a wish)

Item/items (use numbering):